Up to 1/3 of patients on antiplatelet medications may not receive the expected platelet inhibiting effect.\textsuperscript{1}

Patients with inadequate response to their antiplatelet medications may be at significantly greater risk of myocardial infarction, stent thrombosis and death.\textsuperscript{2,5}

The VerifyNow Aspirin Test is a qualitative test to aid in the detection of platelet dysfunction due to aspirin ingestion.

**What is Reported?**

The lab report may look similar to the following:

<table>
<thead>
<tr>
<th>Result Name</th>
<th>Result</th>
<th>Units</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platelet Response</td>
<td>ASPIRIN</td>
<td>400</td>
<td>ARU</td>
</tr>
</tbody>
</table>

(1) Test results are reported in Aspirin Reaction Units (ARU).
\[ \leq 549 \text{ ARU} \quad \text{therapeutic range for platelet function.} \]
\[ \geq 550 \text{ ARU} \quad \text{NON-therapeutic range for platelet function.} \]

Aspirin Reaction Units (ARU) indicate the amount of thromboxane A2-mediated activation of GP IIb/IIIa receptors involved in platelet aggregation.

ARU is calculated as a function of the rate and extent of platelet aggregation. Expected values are in the range of 350-700 ARU. The cut-off to determine if a patient is receiving the therapeutic benefit of aspirin is 549.
Therapeutic Response

ARU values less than 550 are consistent with a patient who is receiving the therapeutic benefit of aspirin.

Pre-Surgical Screen

Prior to surgery, the VerifyNow Aspirin Test can aid in guiding clinical decisions whether to discontinue aspirin therapy or to remain on aspirin to improve graft patency. Medical research suggests that there is patient variability in response to aspirin. Values less than 550 ARU are reported if the patient is receiving the therapeutic benefit of aspirin. After aspirin discontinuation, ARUs less than 550 indicate platelets remain inhibited by aspirin.

Conditions that May Affect Test Results:

- Patient’s exposure to GP IIb/IIIa inhibitors within 48 hours of eptifibatide (Integrilin®), or 14 days of abciximab (ReoPro®).
- Improper sample collection (platelet activation).
- Hematologic related issues: Hct, Platelet Count

The VerifyNow Aspirin Test results should be interpreted in conjunction with other clinical and laboratory data available to the clinician. Integrilin is a registered trademark of Millennium Pharmaceuticals. Reopro is a registered trademark of Centocor, Inc. Plavix is a registered trademark of Sanofi-Synthelabo, Inc.

For more details, see the VerifyNow Test package insert.